This grant will provide support for the Statistics and Data Management Center (SDMC) of the ECOG- ACRIN Cancer Research Group. The SDMC is organized and operated jointly by the Department of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute (DFCI), the Department of Biostatistics at Brown University, the ECOG-ACRIN Medical Research Foundation (EAMRF), and the American College of Radiology (ACR), under the direction of the Group Statisticians. The primary responsibility for data collection and management belongs to the Data Management Center, consisting of EAMRF and ACR. The primary responsibility for study design, monitoring, and analysis, and for overseeing and coordinating SDMC operations, belongs to the Biostatistics Center, consisting of DFCI and Brown University. The primary contact site for grant administration is DFCI. ECOG-ACRIN is a multi-modality group conducting a wide range of studies, including definitive phase III trials of therapeutic interventions, earlier phase studies developing new therapies, studies focused on diagnosis and of advanced imaging methods, investigation of laboratory and imaging based biomarkers, and studies incorporating patient reported outcomes. The SDMC is responsible for all quantitative aspects of EA's activities. Our overall goals are to conduct clinical trials to the highest standards in statistical methods, data management, and regulatory compliance, while continually improving efficiency of all of our processes and systems to optimize the use of our limited resources. Areas of particular focus in this grant include studies incorporating tissue and imaging biomarkers to direct therapy, studies of immunotherapy, studies of de-intensification of therapy to reduce morbidity, studies investigating novel biomarkers, and studies investigating the relationship of biomarkers and therapy in populations defined by race, ethnicity, gender, and age.

Public Health Relevance

The overall purpose of this grant is to provide expertise in statistics and data management to support the research mission of the ECOG-ACRIN Cancer Research Group. Achievement of our objectives will enable ECOG-ACRIN to continue to produce high quality clinical studies that advance the care of cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180794-08
Application #
10116298
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
2014-04-29
Project End
2025-02-28
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
8
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Swinnen, Lode J; O'Neill, Anne; Imus, Philip H et al. (2018) Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05). Oncotarget 9:766-773
Estabrook, Ryne; Cella, David; Zhao, Fengmin et al. (2018) Longitudinal and dynamic measurement invariance of the FACIT-Fatigue scale: an application of the measurement model of derivatives to ECOG-ACRIN study E2805. Qual Life Res 27:1589-1597
Harshman, Lauren C; Chen, Yu-Hui; Liu, Glenn et al. (2018) Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol 36:376-382
Henderson, Tara O; Parsons, Susan K; Wroblewski, Kristen E et al. (2018) Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. Cancer 124:136-144
Dahlberg, Suzanne E; Gray, Robert J (2018) Pragmatic approaches to address expansion cohort design. Cancer 124:3290-3292
Rakovitch, E; Gray, R; Baehner, F L et al. (2018) Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. Breast Cancer Res Treat 169:359-369
Ristau, Benjamin T; Manola, Judi; Haas, Naomi B et al. (2018) Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial. J Urol 199:53-59
Wong, Yu-Ning; Manola, Judith; Hudes, Gary R et al. (2018) Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial. Clin Genitourin Cancer 16:e315-e322
Scott, David W; King, Rebecca L; Staiger, Annette M et al. (2018) High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood 131:2060-2064

Showing the most recent 10 out of 187 publications